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Background: This meta-analysis aims to ascertain the significance of early lung toxicity with 3-Dimensional (3D)
conformal irradiation for breast carcinomas and identify the sub-groups of patients with increased risk.
Methods: Electronic databases, reference sections of major oncological textbooks and identified studies were
searched for synonyms of breast radiotherapy and radiation pneumonitis (RP). Major studies in thoracic irradiation
were reviewed to identify factors frequently associated with RP. Meta-analysis for RP incidence estimation and odds
ratio calculation were carried out.
Results: The overall incidence of Clinical and Radiological RP is 14% and 42% respectively. Ten studies were
identified. Dose-volume Histogram (DVH) related dosimetric factors (Volume of lung receiving certain dose, Vdose
and Mean lung Dose, MLD), supraclavicular fossa (SCF) irradiation and age are significantly associated with RP, but
not sequential chemotherapy and concomitant use of Tamoxifen. A poorly powered study in IMN group contributed
to the negative finding. Smoking has a trend towards protective effect against RP.
Conclusion: Use of other modalities may be considered when Ipsilateral lung V20Gy > 30% or MLD > 15 Gy. Extra
caution is needed in SCF and IMN irradiation as they are likely to influence these dosimetric parameters.
Keywords: Breast radiotherapy, Radiation pneumonitis, Lung toxicity, Meta-analysisIntroduction
Postoperative radiotherapy (RT) after the breast conser-
vative surgery (BCT) or mastectomy, have been shown to
reduce the rates of local recurrence and death in breast
carcinomas (BC) [1-5]. It is the standard practice to offer
patients adjuvant RT to whole breast or chest wall, with
or without loco-regional RT (LRRT), depending on the
stage of disease. The regional fields include the ipsilateral
supraclavicular fossa (SCF). The Axilla (Ax) and internal
mammary nodal region (IMN) RT is uncommon due to
the toxicities associated with them [6-10].
Radiation pneumonitis (RP) and lung fibrosis are two
known toxicities that arise from incidental irradiation of
adjacent ipsilateral lung in BC. Other toxicities include* Correspondence: gokudroid@gmail.com
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reproduction in any medium, provided the orbreast fibrosis, cardiac toxicity, skin toxicity and lymphoe-
dema of the ipsilateral upper limb. The risk of cardiac tox-
icity in tangential radiotherapy treatment of left breast or
chest wall is well studied in literature [6-8]. However most
studies were pre-conformal CT-based planning and IMN
irradiation was a common practice then.
RP and lung fibrosis is believed to represent the different
ends in the clinical course of the disease rather than separ-
ate entities altogether. The natural history of the radiation
lung injury can be divided into 5 phases: immediate phase
(hours to days); latent phase; acute exudative/clinical RP
phase (4–12 weeks post-RT); intermediate phase with
resolution of exudate and deposition of fibroblast and the
final phase when fibrosis is established (usually 6–12 months
post-RT) [11-13]. Type II pneumocytes which produce
surfactant are the cells associated with RP [13,14].
Literature on RP in breast irradiation is very hetero-
geneous: different simulation techniques (conventional
fluoroscopy-based versus CT-based), different treatmentLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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conformal CT-based], different sites treated (chest wall/
breast +/− Ax/SCF/IMN) and also use of electrons to
treat the chest wall +/− IMN after mastectomy.
McDonald et al. [11] reported in 1995, the incidence
of radiological and clinical RP to be in the range of 27 –
40% and 0 − 10% respectively in patients with BC under-
going radiotherapy based on 2 studies in 1980. The
details of the radiotherapy techniques and the grades
of both radiological and clinical RP were not mentioned
in that review. These figures are the most likely estimates
of RP incidence in non-conformal planning days.
Currently there is a trend towards minimizing toxicity
to organs at risks in the adjuvant treatment of breast
cancer. The newer RT modalities or techniques used include
Intensity Modulated Radiotherapy (IMRT), Tomotherapy,
Accelerated Partial Breast Irradiation (APBI) and Intra-
operative Radiotherapy (IORT). IMRT and Tomotherapy
produce more conformal radiation delivery at the expense
of increased integral dose. These newer modalities are
more expensive and needs longer planning time. Smith
BD et al. [15] has recently shown that the adoption of
IMRT for BC in the United States have increased the
cost of breast irradiation significantly.
In centers where there are limited resources or financial
constraints, it is important to allocate the available re-
sources accordingly without compromising the breast
cancer patient’s treatment outcome. Hence the important
questions are:
1. Which patient subgroups will benefit from these
newer modalities of treatment in regards to early
lung toxicity?
2. What are the dosimetric parameters, treatment
factors and patient factors which predict for RP or
early lung toxicity in adjuvant 3-Dimensional
Conformal RT (3D-CRT) for BC?
Methodology
Electronic databases were searched from 1995 till April
2011 (3D-CRT techniques would have been very unlikely
before 1995) using the following inclusion and exclusion
criteria for adjuvant RT studies in BC:
Inclusion Criteria:
The use of 3D-CRT.
Tangential photon fields or electrons for breast/chest
wall treatment +/− LRRT.











The use of Tomotherapy, APBI, interstitial implants,
IORT or IMRT.
Inoperable BC.
Search was performed using PubMed search builder
for Breast Radiotherapy AND Meta-analysis (or Systematic
review); Breast Radiotherapy AND Toxicity; Breast AND
Radiotherapy AND Pneumonitis. This produced 536 hits.
Cochrane library, Google Scholar and reference sections
of the major Radiation Oncology textbooks were searched
to ensure no important studies were missed. Eight studies
from these results were initially identified for the analysis
and two further studies were identified by searching the
reference sections of those 8 studies. Although four of
the identified studies had overlapping data, different
endpoints were used in the analysis [16-19]. Only one
retrospective study was included [20].
Factors affecting the incidence and severity of RP were
identified from the above studies and other thoracic
irradiation studies (lung, oesophagus, lymphoma and
others), which reported on RP. These were dosimetric
parameters (Vdose and MLD), patient factors (smoking
and age) and treatment factors (SCF and IMN RT; con-
comitant Tamoxifen and sequential chemotherapy).
Radiological RP grading criteria used include Arrigada,
modified lung fibrosis CTC (common toxicity criteria)
and Nishioka system [21]. The grouping of low grade
radiological RP in this analysis are: Modified Arrigada
grade 1 in Holli’s study [19] and Arrigada scores 1–3 in
Goldman’s study [22]. Any grades or scores above these
values are grouped as high grade radiological RP. The
clinical RP is also divided into low and high grades with
clinical RP grade 1 classified as low grade and clinical
RP grade 2 or more grouped as high grade.
Statistical methods
Data was analysed using Stata® software, version 11.0
(Stata Corp College Station, TX, USA), and level of sig-
nificance set at 5%. To estimate the incidences of clin-
ical RP and radiological RP, we pooled the values from
each study, using the random effects meta-analysis model.
As for the association between treatment-related factors
and RP, we combined the individual effect sizes (Odds
Ratios) using the random-effects model, using the
method of DerSimonian and Laird, with the estimate of
Gokula et al. Radiation Oncology 2013, 8:268 Page 3 of 12
http://www.ro-journal.com/content/8/1/268heterogeneity being taken from the inverse-variance
fixed-effect model. Heterogeneity between studies was
assessed by the chi-square test for heterogeneity as well
as examining the i-squared statistic, which quantifies
the level of heterogeneity. In the event of heterogeneity,
we used the random effect model instead of the fixed-
effect model to analyse the data. Publication bias for the





The overall incidence of radiological RP in our meta-
analysis [Figure 1] is 42% (95% CI = 22-62%) with large
heterogeneity in the included studies (I-squared = 97.4%,
p < 0.001) and Egger’s test did not show significant pub-
lication bias (p = 0.151). In the study by Marco Krengli et al.
[23], the high detection rate of RP (85%) could be attrib-
uted to the use of high resolution CT images for post
radiotherapy lung assessment. The incidence of RP was
low, as reported by Akiko Kubo et al. [24] because only
tangential RT fields were used and the RP assessment
was mainly done by Chest X-ray (CXR).
The overall incidence of low grade and high grade radio-
logical RP are 22% (95% CI = 17-27%) and 12% (95% CI =
9-33%) respectively. The I-squared heterogeneity index
for low grade radiological RP is 1.7% (p = 0.313) and
97.5% (p < 0.001) for high grade.
Clinical radiation pneumonitis
The overall incidence of clinical RP [Figure 2] is 14%
(95% CI = 8-21%) with large heterogeneity in the included
studies (I-squared = 89.7%, p < 0.001). The Egger’s test
did not show significant publication bias (p = 0.376).Figure 1 Meta-analysis: Incidence of radiological RP with 3D-CRT forEither CTC2.0 or CTC3.0 assessment was used in the
studies. There are no reported cases of CTC grade 4 or
5 toxicity in any of the studies.
The overall incidence of low grade and high grade clin-
ical RP is 14% (95% CI = 9-18%) and 4% (95% CI = 2-7%)
respectively. There is also large heterogeneity in the studies
with I-squared = 79.3% (p = 0.002) and I-squared = 82.4%
(p = 0.001) for low and high grade clinical RP respectively.
The Egger’s test for publication bias is not significant
for either low or high grade clinical RP (p = 0.855
and 0.407).DVH-related parameters
Volume of lung receiving a specified dose [Vdose ]
A systematic review by George Rodrigues et al. [25] in
2004 analysed 5 trials and reported a strong correlation
between Vdose and RP in lung tumour irradiations. In con-
tast, Vdose of the lung in breast or chest wall irradiation is
likely to be smaller in value and hence we limit our ana-
lysis to studies reporting on V20Gy to V25Gy [Table 1]
though some studies do report on other Vdose values.
Berit Wennberg et al. [16] analyzed 121 patients who
had node-positive stage II BC, which was a subgroup
from the main study by Perh Lind et al. [17]. He pre-
sented the data in the form of mean cumulative ipsilateral
lung DVHs for four different treatment techniques. Data
extracted from this paper showed that treatments tech-
niques with V20Gy ≤ 20% had a lower incidence of RP
compared to V20Gy > 20% (12.5% vs 28.4% respectively).
Perh Lind et al. [26] also looked at a subgroup of 128
patients from his earlier paper [17]. He analyzed the
data using the ROC (receiver operating characteristics
curves), which showed the significance of ipsilateral V20Gy
in clinical RP (p = 0.008) and radiological RP (p = 0.009).BC in world literature.
Figure 2 Meta-analysis: Incidence of clinical RP with 3D-CRT for BC in world literature.
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MLD is also significantly correlated with the incidence
and grade of RP, mostly in studies involving lung cancer
or other thoracic irradiations [27-30]. However the data
on MLD in BC is very limited [Table 2].
Though these studies used different end points, all of
them showed significant impact of MLD on lung toxicity.
As with the Vdose, the study by Perh Lind et al. showed
significant correlation between increasing MLD and the
grade of lung toxicity using gamma statistics (p < 0.001)
[17]. The MLD was 7.5 Gy, 13.5 Gy and 16.0-16.6 Gy
for no RP, mild RP and moderate RP respectively.
In Zsusana Kahan’s study 20.5% of patients with radio-
logical RP developed clinical symptoms. The MLD of
patients with no RP versus RP in this study was 12.2 Gy
vs 15.0 Gy respectively [31].
Treatment factors
SCF irradiation
Current meta-analysis shows a significant effect of SCF
irradiation on the incidence of RP [Figure 3]. The odds
ratio (OR) of having RP in this group is 5.07 (95% CI =
1.95-13.22). The heterogeneity between the studies
(I-squared) is 70.1% (p = 0.035).
The subgroup analysis of 121 patients with node posi-
tive stage II BC by Berit Wennberg et al. also showed
significant effect of SCF irradiation on RP [16].
IMN chain irradiation
Figure 4 shows that OR of having RP with IMN irradiation
is 1.04 (95% CI = 0.43-2.54) and there is no statistically
significant heterogeneity between the studies (I-squared =
66.3%, p = 0.052). The study by Goldman et al. had only
9 patients in the no IMN RT group [22]. The fields
used in the IMN irradiation in the studies above vary
significantly and they included oblique electron beam,
anterior photon beam or deep oblique field.
Concomitant tamoxifen
The evidence of Tamoxifen causing lung fibrosis is so far
unclear [32,33]. The OR of having RP with concomitantTamoxifen use is 1.20 (95% CI 0.57 – 2.51) and hetero-
geneity index (I-squared) is 69.1% (p = 0.039).
Sequential chemotherapy-RT
Data on sequential chemotherapy and RP in breast ir-
radiation is very scarce in the literature. Most studies
looked at individual chemotherapeutic agents especially
the taxane group [34,35]. The analysed studies are het-
erogeneous with multiple agents used, different doses
and intensity of the chemotherapy. For example, Lind
et al. (Sweden) [17] reported the use of CMF, FEC, dose
intensified FEC and high dose chemotherapy with stem
cell rescue. Kubo et al. [24] and Lind et al. (Duke’s) [20]
did not mention the type of chemotherapy in their
studies.
The OR of having RP in this group is 1.40 (95% CI =
0.44–4.50) with I-squared = 88.5% (p < 0.001) for hetero-
geneity of the included studies.
Patient factors
Smoking
The effect of smoking on RP has been studied in a few
trials involving thoracic irradiation. In two lung cancer
studies [36,37], smoking has been associated with lower
incidence of lung toxicity.
This positive effect of smoking is also seen in a trial by
Leif Bjermer et al. [38] which looked at inflammatory re-
sponse in breast cancer patients by bronchoalveolar lav-
age. Another large retrospective review by Silvia
Johansson et al. [39] looked at 405 women who under-
went radiotherapy for breast or oesophageal cancers also
showed similar findings.
Our analysis [see Figure 5] shows the OR of having RP
in this smoking-group is 0.59 (95% CI = 0.26 – 1.34) with
heterogeneity index (I-squared) of 70.1% (p = 0.035).
Age
Lung irradiation studies showed conflicting results of
age in predicting for RP [28,36,40-42]. See BC studies in
Table 3.
Table 1 Relationship between dose volume parameters and early lung toxicity in 3D-CRT for BC in world literature
Author, Year of data collection Country n RP endpoint Prognostic groups Test type p value Comments
Perh Lind et al. 1994–1998 [17] Sweden 475 Clinical RP CTC-NCIC Ipsilateral V20Gy: ≈7%,≈20%,
≈30%,≈35%
2 sided Gamma statistics,
G = 0.638
<0.001 Correlation between increasing V20Gy
to grade of lung toxicity. Assessed at
1,4 and 7 months.
Zsusana Kahan et al. 2001–2004 [31] Hungary 119 Radiological RP – CTC 2.0 Mean Ipsilateral V20Gy (%)
(RP- vs RP+)
Student’s t-test (24.8% vs
31.1%)
0.005 3 and 12 months post RT CT-Thorax.
Javier Jaen et al. 2002 [44] Spain 39 Change in perfused volume(%) Bilateral V20Gy Corr. Coefficient r = −0.414 0.026 6,12 and 36 months lung perfusion test.
Marco Krengli et al. 2002 – 2003 [23] Italy 41 Radiological RP (G0-3) Ipsi V25Gy ANOVA 0.0007(G2 vs G0) 3 and 9 months post RT CT-Thorax.
0.02 (G3 vs G0)
Ulla Goldman et al. 2003 – 2005 [22] Sweden 40 Radiological RP – Arigada score Mean Ipsilateral V20Gy (%)
(RP- vs RP+)
24% vs 30% - 4 months (CT-Thorax) and 5 months
(CXR).
Akiko Kubo et al. 2005 – 2007 [24] Japan 413 Radiological RP – CTC/AE 3.0 Ipsi V20Gy≤ 9.7%, Ipsi
V20Gy≥ 9.8%
Cox regression RR = 0.67 0.13 (NS) 3 monthly CXR for 1 year. Only tangential
whole breast irradiation.

















Table 2 Relationship between MLD and early lung toxicity in 3D-CRT for BC in world literature
Author, Year of data collection Country n RP endpoint Test type, p value
Perh Lind et al. 1994–1998 [17] Sweden 475 Clinical RP CTC-NCIC Gamma statistics G = 0.669 <0.001
Zsusana Kahan et al. 2001–2004 [31] Hungary 119 Radiological RP – CTC 2.0 Student’s t-test (RP + vs RP-) 0.003
Javier Jaen et al. 2002 [44] Spain 39 Change in perfused volume (%) Correlation coefficient, r = −0.447 0.013
RP radiation pneumonitis, n number of patients, CTC/CTC-NCIC common toxicity criteria, RT radiotherapy, MLD mean lung dose.
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The early radiation induced pulmonary toxicity has
been well studied in other thoracic irradiation, mostly
involving lung cancers. Caution is needed in extrapolat-
ing the data in lung tumors to breast cancer patients.
The demographics of the patients may differ significantly
as can be seen in the proportion of smokers, age group,
effect of the tumor itself on the lung function and also
the location of the lung that is irradiated. Furthermore,
the lung in BC patients is a healthy organ in contrast to
lung cancer patients.
The major limitation that the authors faced in com-
pleting current analysis is the heterogeneity of the data
in world literature, such as the clinical endpoints meas-
urement, radiological and clinical RP grading system,
different sensitivity in the detection tests of the radio-
logical RP and the poor reporting of confounding factors
in some studies.
Besides the dosimetric, treatment and patient factors
mentioned earlier, other reported factors are pre-irradiation
lung function and performance status, pre-existing re-
spiratory diseases (chronic obstructive airway disease,
interstitial pneumonitis, etc) and genetic predisposition.
There is very little or no data on contribution of this
factors in 3D-CRT for BC towards early lung toxicity
and hence no analysis can be done.Figure 3 Meta-analysis: Effect of SCF irradiation on RP in 3D-CRT for BRadiological and clinical RP
The previous review by Mc Donald et al. [11] in 1995
have reported incidence of radiological RP in range of
27 – 40% and clinical RP in to be in the range of 0-10%.
The overall incidence of radiological RP in current meta-
analysis is 42% (95% CI = 22-62%) which is marginally
higher compared to the previous review by Mc Donald
et al. This may be due to the use of more CT scans in
current studies.
Clinical relevance low grade or high grade radiological
RP leading to late lung toxicity is not well known cur-
rently and is an area for further research not only in breast
cancer patients but also other thoracic irradiations. Five
studies in current analysis have shown poor correlation
between radiological RP and clinical RP [18,19,22,31,43].
Fourteen per cent incidence of clinical RP in current
analysis (95% CI = 8-21%), is also higher than the previous
estimate by McDonald.. This can be due to more vigilant
assessment by the physicians in current clinical trial
settings. Furthermore, McDonald and colleagues only
reported approximate values and the precise informa-
tion was not always reported in the quoted studies.
The late sequelae of low or high grade clinical RP is
also not well known currently, as with radiological RP.
A subgroup analysis of 121 patients with stage II, node
positive breast cancers by Berit Wennberg et al. [16]C.
Figure 4 Meta-analysis: Effect of IMN irradiation on RP in 3D-CRT for BC.
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Perh Lind et al. [17]) showed a slightly higher incidence
of 23.1% clinical RP compared to 18.9% in the main study.
This is probably due to the fact that the 475 patients
recruited into the main study may include the mixture
of very early stage disease who may not have had re-
gional RT.
The reported incidences of clinical and radiological
RP vary significantly between studies as seen in the
test for heterogeneity (I-squared). This can be attrib-
uted to the different techniques, fields used and meas-
urement variations of RP. Though the assessment of
clinical RP is quite standardized using either CTC2.0
or CTC3.0 toxicity criteria, the threshold to diagnose
clinical RP may vary significantly between physicians
and between centers.Figure 5 Meta-analysis: Effect of smoking on RP in 3D-CRT for BC.DVH related dosimetric factors
The DVH related parameters (Vdose and MLD) are strongly
associated with the clinical RP, radiological RP and change
in physiologic lung functioning in the current analysis.
The study by Akiko Kubo et al. [24] was insignificant
most likely because of low ipsilateral V20Gy of 9.6% (mean)
and 18.8% (maximum).
In another study, Javier Jaen et al. [44] had shown
that bilateral V20 was closely correlated to the change
in perfused volume. However it is beyond the scope of this
paper to discuss the merits of physiological or functional
lung damage assessment.
It is difficult to deduce the exact threshold value of
V20Gy for clinical practice from this meta-analysis. How-
ever, other RT techniques or modalities can be considered,
when ipsilateral V20Gy > 30% [17,22,31]. Some clinical
Table 3 Relationship between age and radiation pneumonitis in 3D-CRT for BC in world literature
Author, Year* Country n RP endpoint Prognostic groups Test type (results) p value Comments
Lind et al. 1994–1998 [20] Duke’s 613 Clinical RP, Grade > 2 Median age Mann–Whitney test 0.64 RP > Grade 2 only (retrospective)
(RP- vs RP+) (54.9 yrs vs 55.2 yrs)
Lind et al. 1994–1998 [17] Sweden 180 Clinical RP CTC-NCIC Mean age Students t-test <0.001 Loco-regional RT after mastectomy
(RP- vs RP+) (55.4 yrs vs 62.6 yrs)
Kahan et al. 2001 – 2004 [31] Hungary 119 Radiological RP – CTC 2.0 Mean age Student’s t-test 0.012 -
(RP- vs RP+) (56.2 yrs vs 61.5 yrs)
Jaen et al. 2002 [44] Spain 39 Perfused lung volume (%) ≤55 yrs, >55 yrs Box plot: ≤55 yrs vs >55 yrs NS Reduced perfusion in older age group
Kubo et al. 2005 – 2007 [24] Japan 413 Radiological RP – CTC/AE 3.0 ≤50 yrs,>50 yrs Cox regression model 0.20 Only tangential whole breast irradiation
(RR = 0.76, 95% CI 0.49 – 1.2)
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bilateral breast radiotherapy and locally advanced BC.
The ipsilateral V20Gy should be kept below 24% if possible
without compromising the required RT field coverage.
The study by Akiko Kubo et al. [24] implies that further
attempts at reducing ipsilateral V20Gy below 20% may not
be of any benefit.
There are other models in radiation induced lung
injury that are not analyzed in this paper such as the
normal tissue complication probability (NTCP) model
and more advanced biologically based models [25,45,46].
There is very limited data on the use of these models
in BC.
The large study of lung cancer patients by Kwa et al.
[27] addressing RP have recommended the use of MLD
or NTCP to predict the risk of RP. MLD is also found to
be highly correlated to V20Gy in lung irradiation studies
[27,29]. The three studies quoted in this current analysis
do show a strong relationship between MLD and early
lung toxicity. Based on the studies by Perh Lind et al.
[17] and Zsusana Kahan et al. [31], it should be safe if
the MLD is limited below the range of 12-15 Gy to avoid
serious lung toxicity in 3D-CRT irradiation for BC.
Other techniques or modalities of radiotherapy may be
considered if MLD exceeds 15 Gy.
Treatment factors
SCF irradiation shows a strong association with RP
incidence (OR = 5.07). The addition of SCF irradiation
increases the amount of lung tissue irradiated and hence
MLD and Vdose [47,48].
The reported incidence of IMN and medial SCF LN
metastasis is between 4-9% in axillary node negative
patients and 16-52% in axillary node positive patients
[49-52]. Despite the reported toxicities, positive out-
comes from 2 studies by Overgaard M et al. [2,3] have
renewed the interest in IMN irradiation as part of LRRT.
Furthermore, modern conformal techniques are likely
to reduce the heart dose. The current view of IMN
irradiation may change depending on the outcome of
EORTC trial 22922/10925 which completed accrual
in 2004 and results are expected in 2012 [49]. The three
years toxicity profile update of 4004 patients with IMN-
medial SCF field irradiation reported a 4.3% lung tox-
icity rate in the IMN arm versus 1.3% in no IMN arm
(p < 0.0001). There were no statistically significant dif-
ference between the two groups with regards to car-
diac toxicity. Poorly powered study by Goldman et al.
(9 patients in no-IMN RT group) [22] caused the non-
significant findings in current meta-analysis.
Concomitant use of Tamoxifen has no statistically sig-
nificant effect on RP in this meta-analysis, as in earlier
studies [32,33]. Three large retrospective studies [53-55]
examined the concomitant and sequential Tamoxifen inBC patients, and concluded that the use of both con-
comitant and sequential Tamoxifen was acceptable in
terms of local relapse, distant metastasis and secondary
malignancies. There was no statistically significant differ-
ence in lung toxicity between the groups.
The influence of concurrent chemotherapy-RT on RP
incidence has been well studied in thoracic irradiation
[11,28,56] and also two BC studies [11,57]. Concurrent
chemotherapy-RT is not analyzed in current paper as it
is seldom practised nowadays.
Data on sequential chemotherapy and RP in breast
irradiation is very scarce in the literature [34,35]. Our
result is not significant probably because of heteroge-
neous studies. Adjuvant Taxanes and Cyclophosphamide
or biological agents (Bevacizumab) [58] have been re-
ported to increase the risk of RP. Anthracyclines and
Taxanes [59] are potent radiosensitizers. Cyclophospha-
mide have been reported to cause lung injury with or
without the addition of RT in some case series [60].
Radiation recall can occur if Paclitaxel is used after
RT and can cause pathological changes in the lungs at
the previous RT field. Hence readers are encouraged to
refer to data on individual drugs in the literature for
clinical practice.
Patient factors
There is a trend towards protective effect for smokers in
breast irradiation in our meta-analysis. This effect was
also reported in two other studies of thoracic irradiation
[36,37]. This finding is quite puzzling because we expect
that smokers with already damaged lung would be more
susceptible to radiation induced lung injury. Some pos-
sible explanations are: 1) smokers may have higher
threshold to develop clinical symptoms due to their already
damaged epithelium; 2) the local immune reaction may not
be as strong as non-smokers due to the damage to
immune cells such as tissue macrophages in the lung
epithelium causing reduced antibody secretion and exu-
dates; 3) tissue hypoxia in smokers may have radio pro-
tective effect; 4) lung scarring in smokers may mask the
appearance of RP on CT scans.
In current analysis, there is a conflicting effect of age
on both radiological and clinical RP in 3D-CRT for BC.
The studies by Akiko Kubo et al. [24] and Perh Lind
et al. (Duke’s) [20] did not show statistically significant
effect of age. In the former study, only tangential whole
breast irradiation was used and the volume of irradiated
lung was very small. There could have been significant
bias in retrospective data in the latter study.
Based on the other three studies, age > 55 yrs is a risk
factor for RP in 3D-CRT for BC. However, the long term
effect of early lung toxicity is not known and may
take many years before it becomes clinically significant,
especially in the younger age group.
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literature but not discussed here is the radiation-
induced bronchiolitis obliterans organizing pneumonia
(BOOP) syndrome in which the lung injury occurs out-
side the radiation field or even in the contra-lateral lung.
Kubo et al. have reported 2.9% incidence of BOOP syn-
drome with all cases of radiological RP ≥ grade 2 devel-
oping BOOP syndrome. A survey in major hospitals in
Japan from August 1999 to March 2000 showed an inci-
dence of 1.8-2.19% in patients radiated after BCT [24,61].
Conclusion
The DVH-related parameters (Vdose and MLD) and SCF
irradiation are the strongest parameters associated with
RP. Attempt should be made where possible to keep the
ipsilateral lung V20Gy < 24% and MLD< 15 Gy without com-
promising the required radiotherapy coverage. Other
RT techniques can be considered when ipsilateral lung
V20Gy >30 Gy or MLD > 15 Gy. Other factors that increase
the risk of RP are age >55 yrs and probably IMN irradi-
ation. However, caution is needed in treating younger age
group due to the possibilities of late sequealae.
Concomitant Tamoxifen do not increase the risk of
developing RP. Readers are encouraged to search the data
on individual chemotherapeutic agents for clinical prac-
tice. Though smoking is noted to have protective effect,
this can just be a masking effect rather than physiological
protection against radiation induced damage.
Biochemical markers can be another factor to predict
for early lung toxicity in 3D-CRT for BC. The combin-
ation of elevated transforming growth factor (TGF)-beta1
levels during RT and MLD has been reported as having
predictive value in non-small cell lung cancers [62]. This
together with use of radioprotectors such as Pentoxifylline
can be an area for further research in RP [63].
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